Skip to main content

Table 3 Characteristics of patients with ILD distributed outside the high-dose (> 40 Gy) irradiated area (type II)

From: Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer

Patient characteristic

 

Treatment

 

ILD

patient

 

HbA1c (%)

 

chemotherapy

durvalumab

V20 (%)

V5 (%)

 

ILD onset timing1) (days)

NCI-CTCAE version 5.0 Grade

1

 

8.2

 

–

–

30.4

46.5

 

126

3

2

 

9.1

 

–

–

10.8

17.7

 

28

1

3

 

8.1

 

+

–

40.6

55.8

 

28

3

4

   

+

+

39.3

70.3

 

73

2

5

 

6.5

 

–

–

27.0

39.7

 

11

1

6

 

6.9

 

+

–

21.9

34.0

 

41

2

7

 

7.8

 

+

+

28.0

40.7

 

33

1

8

 

5.5

 

+

+

24.2

36.8

 

50

2

9

 

6.2

 

+

–

31.4

42.1

 

9

2

10

 

11.5

 

+

+

28.4

46.7

 

37

2

11

 

5.7

 

+

+

15.6

26.4

 

122

3

12

 

6.2

 

+

–

32.0

46.2

 

63

1

  1. Abbreviations
  2. ILD: interstitial lung disease
  3. CT: computed tomography
  4. NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events
  5. HbA1c: hemoglobin A1c
  6. Vx: proportion of the volume receiving ≥ x Gy
  7. 1) ILD onset timing: days from RT to the onset and/or diagnosis of ILD
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us